Skip to main
OMER

Omeros (OMER) Stock Forecast & Price Target

Omeros (OMER) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Omeros is well-positioned for future success with a stronger financial profile and recent operational progress, particularly in their YARTEMLEA and complement pipeline programs. The company has achieved key milestones, including a J-code assignment and successful launch of YARTEMLEA. Upcoming catalysts, such as a regulatory decision in 2026, continued launch execution and awareness, and a fully built U.S. field organization, could drive further growth and aid in the company's capital deployment plans.

Bears say

Omeros is facing several fundamental risks, including clinical and regulatory risk, partnership risk, financial risk, commercial risk, legal and intellectual property risk, and market share risk. Additionally, while the new J-code for its YARTEMLEA drug may improve visibility around reimbursement and use, there are still concerns about administrative delays and uptake in a rare, high-acuity setting. The company's financials also show a decline in royalty revenues, further adding to the negative outlook.

Omeros (OMER) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Omeros and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Omeros (OMER) Forecast

Analysts have given Omeros (OMER) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Omeros (OMER) has a Strong Buy consensus rating as of May 1, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $40.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $40.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Omeros (OMER)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.